ALEMBIC PHARMACEUTICALS
|
ALEMBIC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 34.33 | 29.68 | 31.33 | 17.40 | 26.50 |
| CEPS(Rs) | 50.34 | 43.78 | 45.20 | 31.41 | 41.09 |
| DPS(Rs) | 12.00 | 11.00 | 11.00 | 8.00 | 10.00 |
| Book NAV/Share(Rs) | 288.72 | 264.10 | 245.14 | 222.36 | 266.47 |
| Tax Rate(%) | 3.33 | 17.70 | 2.53 | 3.55 | 16.70 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 7.84 | 7.48 | 14.97 | 12.53 | 16.48 |
| EBIT Margin(%) | 5.53 | 5.86 | 11.05 | 7.16 | 12.12 |
| Pre Tax Margin(%) | 4.87 | 5.27 | 10.14 | 6.27 | 11.79 |
| PAT Margin (%) | 4.71 | 4.34 | 9.89 | 6.05 | 9.82 |
| Cash Profit Margin (%) | 6.94 | 6.42 | 14.26 | 10.92 | 15.22 |
| Performance Ratios | |||||
| ROA(%) | 8.23 | 8.28 | 9.93 | 5.15 | 7.34 |
| ROE(%) | 12.35 | 11.63 | 13.40 | 7.12 | 10.11 |
| ROCE(%) | 11.74 | 13.51 | 13.42 | 7.44 | 11.25 |
| Asset Turnover(x) | 1.75 | 1.91 | 1.00 | 0.85 | 0.75 |
| Sales/Fixed Asset(x) | 3.16 | 3.36 | 1.70 | 1.79 | 1.97 |
| Working Capital/Sales(x) | 7.31 | 8.01 | 3.84 | 4.44 | 4.64 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.32 | 0.30 | 0.59 | 0.56 | 0.51 |
| Receivable days | 36.70 | 32.99 | 60.69 | 59.84 | 39.75 |
| Inventory Days | 61.45 | 53.50 | 91.38 | 99.60 | 106.49 |
| Payable days | 157.72 | 164.40 | 150.62 | 148.04 | 173.51 |
| Valuation Parameters | |||||
| PER(x) | 19.28 | 31.31 | 31.35 | 28.50 | 27.97 |
| PCE(x) | 13.15 | 21.22 | 21.73 | 15.79 | 18.04 |
| Price/Book(x) | 2.29 | 3.52 | 4.01 | 2.23 | 2.78 |
| Yield(%) | 1.81 | 1.18 | 1.12 | 1.61 | 1.35 |
| EV/Net Sales(x) | 1.93 | 2.90 | 3.15 | 1.82 | 2.85 |
| EV/Core EBITDA(x) | 12.08 | 18.43 | 20.39 | 14.49 | 16.37 |
| EV/EBIT(x) | 17.99 | 24.65 | 28.50 | 25.45 | 23.53 |
| EV/CE(x) | 2.01 | 3.03 | 3.74 | 2.06 | 2.09 |
| M Cap / Sales | 1.77 | 2.74 | 3.10 | 1.72 | 2.75 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.08 | 7.12 | 10.19 | 6.54 | -1.62 |
| Core EBITDA Growth(%) | 11.62 | 9.27 | 35.24 | -23.09 | -41.02 |
| EBIT Growth(%) | 0.21 | 14.23 | 69.98 | -37.06 | -53.53 |
| PAT Growth(%) | 15.26 | -5.49 | 80.07 | -34.35 | -53.27 |
| EPS Growth(%) | 15.66 | -5.26 | 80.07 | -34.35 | -54.56 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.24 | 0.23 | 0.09 | 0.15 | 0.12 |
| Current Ratio(x) | 1.73 | 1.67 | 2.07 | 1.78 | 1.63 |
| Quick Ratio(x) | 0.79 | 0.76 | 0.99 | 0.88 | 0.75 |
| Interest Cover(x) | 8.41 | 9.98 | 12.24 | 8.07 | 36.27 |
| Total Debt/Mcap(x) | 0.10 | 0.07 | 0.02 | 0.07 | 0.04 |
Compare Financial Ratios of peers of ALEMBIC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALEMBIC PHARMACEUTICALS | ₹16,384.6 Cr | -2% | 9.4% | -18.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,786.0 Cr | 0.5% | 6.8% | 16.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,590.0 Cr | 0.6% | 8.7% | 7.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,658.0 Cr | 0.4% | 13.8% | 46.9% | Stock Analytics | |
| CIPLA | ₹115,728.0 Cr | -0.4% | 5.8% | -2.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,708.0 Cr | -1.9% | -5.1% | -2.2% | Stock Analytics | |
ALEMBIC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALEMBIC PHARMACEUTICALS | -2% |
9.4% |
-18.3% |
| SENSEX | 0.5% |
0.1% |
-6.1% |
You may also like the below Video Courses
